In genotype 1 null responders , daclatasvir plus twice-daily asunaprevir DUAL therapy is effective for most genotype 1b patients , and daclatasvir , asunaprevir , and PegIFN/RBV QUAD therapy is effective for nearly all genotype 1a and 1b patients ; but neither DUAL nor TRIPLE therapy is effective for genotype 1a patients .